Furthermore, ibrutinib decreased the synthesis of matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9)—endopeptidases, of which overexpression is associated with increased invasiveness and severity of prostate cancer [96,112,113]. The gene discussed is MMP2; the disease is Familial prostate cancer.